IL1B and macrophage activation syndrome: Among the 22 patients experiencing their first MAS episode under IL‐1–targeted therapy (either anakinra or canakinumab), 32% (7 of 22) also developed a second episode within the median follow‐up of 4.9 years (range 0.4–15.5 years) (Table 1).